advanced search

<< Back To Home

Reduction in Vaccine-Type Human Papillomavirus Prevalence among Women in the United States, 2009–2012

Monday, 9th of January 2017

The Journal of Infectious Diseases, Volume 214, Issue 12, pp. 1961-1964.

1.First published online: November 7, 2016

Reduction in Vaccine-Type Human Papillomavirus Prevalence among Women in the United States, 2009–2012

1.   Abbey B. Berenson1,2,

2.   Tabassum Haque Laz1,a and

3.   Mahbubur Rahman1,a

+ Author Affiliations

1.    ¹Center for Interdisciplinary Research in Women´s Health

2.    ²Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston

1.    Correspondence: A. B. Berenson, Center for Interdisciplinary Research in Women´s Health, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-0587 (abberens@utmb.edu).

1.     ↵a Present affiliations: Health Research and Consulting Services, Dhaka, Bangladesh (T. H. L.); and Center for Clinical Epidemiology, Graduate School of Public Health, St Luke´s International University, Tokyo, Japan (M. R.).

Abstract below; full text is available to journal subscribers.

Between 2009 and 2012, the proportion of young women in the United States completing the human papillomavirus (HPV) vaccine doubled. To understand how quickly this increased uptake is affecting women in the United States, we evaluated the prevalence of vaccine-type (VT) HPV strains among young women in national data sets from 2009–2010 and 2011–2012. Among 18–26-year-old women, the prevalence of VT HPV decreased markedly over a short interval, from 15.4% in 2009–2010 to 8.5% in 2011–2012 (prevalence ratio, 0.51; 95% confidence interval, .28–.92), and the prevalence of high-risk VT HPV decreased from 13.1% to 6.5% (0.46; .25–.86). Reductions in HPV-related diseases will probably follow.